Cheaper liver dialysis machine could be just as effective
NCT ID NCT02310542
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares two machines that clean the blood of toxins when the liver fails: MARS (a standard system) and SPAD (a simpler, cheaper alternative). Thirty-four patients with severe liver failure will try both machines in random order. The goal is to see if SPAD works as well as MARS at removing bilirubin and other toxins.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- albumin dialysis (MARS or SPAD device)
- What this could lead to
- If one system works as well as the other, it could offer a simpler, less expensive way to support liver function in critically ill patients.
- What could go wrong
- This is a small, early-stage study with only 34 participants, so results may not apply broadly. Both systems are temporary supports, not cures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATIC FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital de la Croix Rousse - Service de réanimation chirurgicale
Lyon, 69317, France